Command Palette

Search for a command to run...

Clinical Trials · NCT01076842

Efficacy Evaluation of Different Medication Combination in Type 2 Diabetes Treatment

CompletedPhase 4Exenatide (Approved)
Phase
Phase 4
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
75
Start date
Apr 2008
Locations
2 sites, United States
Primary endpoint
The primary endpoint is the improvement in A1C goal measured in mean reduction in A1c levels over 24 weeks.
View Exenatide compound reference